Evidence map›Paper›PMID 30314461›Full record

ArticleBMC nephrology2018

Associations of sclerostin with carotid artery atherosclerosis and all-cause mortality in Chinese patients undergoing maintenance hemodialysis.

Aiqun Chen, Ying Sun, Ju Cui, Ban Zhao, Haitao Wang, Xianguang Chen, Yonghui Mao

Open access · goldAbstract read
In one paragraph

Article in BMC nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Sclerostin and Vascular Pathophysiology.International journal of molecular sciences · 2020
    Review
  13. Article
  14. Review
  15. Sclerostin: a new biomarker of CKD-MBD.International urology and nephrology · 2020
    Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Aiqun ChenDepartment of Nephrology, Beijing Hospital, National Center of Gerontology, Beijing, People's Republic of China.
Ying SunDepartment of Nephrology, Beijing Hospital, National Center of Gerontology, Beijing, People's Republic of China.
Ju CuiThe MOH Key Laboratory of Geriatrics, Beijing Hospital, National Center of Gerontology, Beijing, People's Republic of China.
Ban ZhaoDepartment of Nephrology, Beijing Hospital, National Center of Gerontology, Beijing, People's Republic of China.
Haitao WangDepartment of Nephrology, Beijing Hospital, National Center of Gerontology, Beijing, People's Republic of China.
Xianguang ChenDepartment of Nephrology, Beijing Hospital, National Center of Gerontology, Beijing, People's Republic of China.
Yonghui MaoDepartment of Nephrology, Beijing Hospital, National Center of Gerontology, Beijing, People's Republic of China. maoyonghui0214@bjhmoh.cn.
Beijing Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrevious clinical studies found inconsistent relationship between circulating sclerostin levels and treatment outcome in patients undergoing maintenance hemodialysis (MHD). Therefore, this study aimed to assess the associations of sclerostin with carotid artery atherosclerosis and all-cause mortality in Chinese patients undergoing MHD.

methodsThis retrospective study assessed 84 patients undergoing MHD at the Nephrology Department of Beijing Hospital from January to April 2012, with a median follow-up of 61.2 months (range: 11.5 to 63 months). Carotid artery intima-media thicknesses (CIMTs) and atherosclerotic plaques were measured by B-mode Doppler ultrasound at baseline. Blood samples were collected for measuring serum sclerostin and soluble klotho (s-klotho) levels. The associations of sclerostin levels with carotid artery atherosclerosis was evaluated by correlation methods. Predictive factors of mortality were assessed by multivariate COX regression.

resultsBaseline serum sclerostin averaged 162.01 pmol/L, with an interquartile range of 121.69 to 225.22 pmol/L, while CIMT values were 1.35 ± 0.39 mm. Carotid artery atherosclerotic plaques were detected in 68 subjects (81%). Subjects with sclerostin levels above the median value had higher CIMT (p = 0.038) and higher prevalence of atherosclerotic plaque (p = 0.025). During follow-up, 27 patients died; Kaplan-Meier curves indicated that subjects with high sclerostin levels (above the median value at baseline) had shorter survival (log rank p = 0.011). In multivariate COX regression analysis, serum sclerostin (HR, 1.095; 95% confidence interval [CI] 1.022-1.174, p = 0.010) and albumin (HR, 0.742; 95%CI 0.612-0.900, p = 0.002) levels were independent predictors of all-cause mortality.

conclusionsSclerostin is positively associated with CIMT. In addition, patients with low baseline serum sclerostin undergoing MHD show better survival.

Indexed as

Asian PeopleAdaptor Proteins, Signal TransducingAdultAgedAged, 80 and overBiomarkersBone Morphogenetic ProteinsCarotid Artery, CommonCarotid Artery DiseasesCarotid Intima-Media ThicknessChinaCross-Sectional StudiesFemaleFollow-Up StudiesGenetic MarkersHumansAdaptor Proteins, Signal TransducingBiomarkersBone Morphogenetic ProteinsGenetic MarkersSOST protein, humanCarotid artery intima-media thicknessMaintenance hemodialysisMortalitySclerostin

Identifiers

PMID30314461
PMCPMC6186107
OpenAlexW2896921385

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.